Skip to content
GHIAA Logo Small
Envelope Linkedin-in Twitter
  • Home
  • Our Work
    • Consulting
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
    • GHIAA News
    • Newsletter
  • Contact
  • search
Menu
  • Home
  • Our Work
    • Consulting
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
    • GHIAA News
    • Newsletter
  • Contact
  • search
 
search

Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement

  • Post author:GHIAA Admin
  • Post published:October 23, 2024
  • Post category:

Continue ReadingGilead, HIV Therapeutic (Lenacapavir) Template License Agreement

Gates Foundation – Visterra, Strategic Relationship Letter Agreement

  • Post author:GHIAA Admin
  • Post published:September 19, 2023
  • Post category:

Continue ReadingGates Foundation – Visterra, Strategic Relationship Letter Agreement

Yale University – BIND Biosciences, Cancer Therapeutic, Exclusive License Agreement

  • Post author:GHIAA Admin
  • Post published:March 3, 2023
  • Post category:

Continue ReadingYale University – BIND Biosciences, Cancer Therapeutic, Exclusive License Agreement

DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement

  • Post author:GHIAA Admin
  • Post published:October 26, 2022
  • Post category:

Continue ReadingDNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement

Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement

  • Post author:GHIAA Admin
  • Post published:September 28, 2022
  • Post category:

Continue ReadingGilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement

AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement

  • Post author:GHIAA Admin
  • Post published:September 14, 2022
  • Post category:

Continue ReadingAXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement

CARB-X Portfolio Company Agreement Template

  • Post author:GHIAA Admin
  • Post published:August 16, 2022
  • Post category:

Continue ReadingCARB-X Portfolio Company Agreement Template

Shionogi – GARDP, Cefiderocol License Agreement

  • Post author:GHIAA Admin
  • Post published:July 8, 2022
  • Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

CEPI – CureVac, Framework Partnering Agreement

  • Post author:GHIAA Admin
  • Post published:March 31, 2022
  • Post category:

Continue ReadingCEPI – CureVac, Framework Partnering Agreement
  • 1
  • 2
  • Go to the next page

Recent Comments

    Archives

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    The development of the MAPGuideⓇ platform and Equitable Access Toolkit was supported by the Wellcome Trust (grant numbers 219632/Z/19/Z, 221648/Z/20/Z and 225262/Z/22/Z).

    If you are interested in providing funding or an in-kind contribution to support GHIAA’s continuing equitable access advocacy work and resource development activities, please contact us using the form below.  

    Global Healthcare Innovation Alliance Accelerator is a 501(c)(3) non-profit recognized by the IRS.

    Contact Us

    Get In Touch

    comms@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Home
    MAPGuide
    About GHIAA
    Team
    News

    Contact Us

    Get In Touch

    comms@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Home
    MAPGuide
    About GHIAA
    Team
    News

    Twitter Linkedin-in Envelope
    comms@ghiaa.org

    Privacy Policy

    • Privacy Policy
    Menu
    • Privacy Policy

    © 2024 Global Healthcare Innovation Alliance Accelerator. All Rights Reserved

    Sign Up to Our Newsletter

    Receive updates about GHIAA’s latest tools, resources and news.

    I consent to receiving email updates from GHIAA and have read and agree to the Privacy Policy and Terms of Service..

    Agreement Type

    • Any Agreement Types
    • Contract Manufacturing
    • License
    • Other
    • R&D Collaboration
    • R&D Funding
    • Supply/Purchase
    • Technology Transfer

    Select Partner Type

    • Any Partner types
    • Academic institution
    • Funder
    • Government
    • Industry
    • Multilateral organization
    • Non-profit research organization
    • Product development partnership

    Select Development Stage

    • Any Develoment stages
    • Discovery/Concept
    • Preclinical
    • Early clinical (through Phase 2)
    • Late clinical (Phase 3)
    • Commercialization
    • Field Testing

    Select Technology

    • Any Technologies
    • Device
    • Diagnostic
    • Drug
    • Vaccine

    Select Issue or Sub-issues

    • Equitable access
      • All Equitable access
      • Donation
      • Ensuring continuity
      • Access plans & principles
      • Preparedness & response
      • Affordable pricing
      • Territory access commitments
    • Business model
      • All Business model
      • Benefit sharing
      • Clinical trial conduct
      • Quality management
      • Regulatory strategy
      • Governance
      • Payment structures
      • Product supply
    • Protecting & sharing information
      • All Protecting & sharing information
      • Confidentiality
      • Information sharing
      • Publication of results
      • Technology transfer
    • Intellectual property
      • All Intellectual property
      • License grants
      • Ownership of IP
      • Protection of IP
    • Liability
      • All Liability
      • Indemnification & liability
      • Insurance
      • Representations & warranties
    • Term & termination
      • All Term & termination
      • Effects of termination
      • Term of agreement
      • Termination & withdrawal